GE HealthCare Technologies GEHC
GE HealthCare Technologies reports $5.51B revenue for Q3 2026
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001932393-26-000059
- Revenue: $5.51 billion for the three months ended Sep 30, 2026
- Net income: $615 million for the three months ended Sep 30, 2026
- Diluted EPS: $1.36 for the three months ended Sep 30, 2026
- Cash and equivalents: $2.83 billion at Sep 30, 2026
Written from the 10-Q on EDGAR. Check the filing before you rely on it.
What changed since last quarter
2 new legal mentions
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $5.51B | $5.3B | +4.1% |
| Operating income and margin | $805M · 14.6% | $739M · 14% | +8.9%, margin +0.6 pts |
| Net income | $615M | $561M | +9.6% |
| Operating cash flow | $907M | $168M | +440% |
| Cash | $2.83B | $2.08B | +36% |
| Backlog (remaining performance obligations) | $16.11B | $16.12B | 0% |
New legal mentions (2)
- The District Court dismissed the complaint in 2020, but that decision was subsequently reversed on appeal and the case was remanded for further proceedings. +2 more paragraphs
- In the three and nine months ended September 30, 2026, the Company received refunds of $55 million and $162 million, respectively, and recognized pre-tax benefits from tariff refunds of $9 million and $115 million, respectively, related to tariffs incurred in 2025 and $4 million and $27 million, respectively, related…
Similar companies
Companies of similar size in SIC 3844 and related industry codes: the same peer list as the financial tables.
- Dexcom DXCM public float $34.2B, Jun 30, 2025
- Resmed RMD public float $34.9B, Dec 31, 2025
- Edwards Lifesciences EW public float $45.9B, Jun 30, 2025
- STERIS STE public float $24.2B, Sep 30, 2025
- Insulet PODD public float $22.1B, Jun 30, 2025